(I), which includes peroral introduction to mammal, which needs drug treatment, of combination of medication, or its pharmaceutically acceptable salt, and atasanavir, or its pharmaceutically acceptable salt.;EFFECT: improvement of pharmakinetic characteristics of medication.;13 cl, 2 dwg, 14 tbl, 7 ex"/>
APPLICATION OF ATASANAVIR FOR IMPROVEMENT OF PHARMAKINETICS OF UGT1A1-METABOLISED MEDICATIONS
首页>
外国专利>
APPLICATION OF ATASANAVIR FOR IMPROVEMENT OF PHARMAKINETICS OF UGT1A1-METABOLISED MEDICATIONS
APPLICATION OF ATASANAVIR FOR IMPROVEMENT OF PHARMAKINETICS OF UGT1A1-METABOLISED MEDICATIONS
展开▼
机译：阿塔那那韦在改善UGT1A1-代谢药物药代动力学中的应用
展开▼
页面导航
摘要
著录项
相似文献
摘要
FIELD: medicine, pharmaceutics.;SUBSTANCE: invention relates to field of pharmaceutics and medicine and concerns method of improvement of pharmakinetic characteristics of peroral medication, directly metabolised by UGT1A1, of formula (I), which includes peroral introduction to mammal, which needs drug treatment, of combination of medication, or its pharmaceutically acceptable salt, and atasanavir, or its pharmaceutically acceptable salt.;EFFECT: improvement of pharmakinetic characteristics of medication.;13 cl, 2 dwg, 14 tbl, 7 ex
展开▼
机译：技术领域：本发明涉及药物和医学领域，并且涉及改进由UGT1A1直接代谢的式<图像文件=“ 00000035.GIF” he =“ 30”的经口药物的药代动力学特性的方法。 imgContent =“ undefined” imgFormat =“ GIF” wi =“ 94” />（I），其中包括将需要药物治疗的哺乳动物，药物或其药学上可接受的盐与atasanavir或其药物组合经口引入可接受的盐;效果：改善药物的药代动力学特性; 13 cl，2 dwg，14 tbl，7 ex
展开▼
